One Way Holdings LLC Acquires 1,301 Shares of Eli Lilly and Company $LLY

Key Points

• One Way Holdings increased its Eli Lilly position by 7.9% in the third quarter, acquiring 1,301 shares for a total holding of 17,852 shares valued at approximately $20.7 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, exceeding analyst expectations. Analysts maintain a largely positive outlook, with a consensus “Moderate Buy” rating and a $1,404.14 target price.
• Despite strong GLP-1 demand and raised analyst targets, investors face risks from high valuation, pricing pressure and revenue concentration in Mounjaro and Zepbound. Insiders sold 13,500 shares worth roughly $16.0 million over the past three months.

One Way Holdings LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,852 shares of the company's stock after acquiring an additional 1,301 shares during the quarter. One Way Holdings LLC's holdings in Eli Lilly and Company were worth $20,656,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in LLY. Vigilare Wealth Management grew its position in shares of Eli Lilly and Company by 32.9% in the third quarter. Vigilare Wealth Management now owns 1,819 shares of the company's stock valued at $2,106,000 after purchasing an additional 450 shares in the last quarter. Welch Group LLC raised its stake in shares of Eli Lilly and Company by 6.9% during the 3rd quarter. Welch Group LLC now owns 16,100 shares of the company's stock valued at $18,629,000 after purchasing an additional 1,036 shares during the period. Trek Financial LLC raised its stake in shares of Eli Lilly and Company by 10.3% during the 3rd quarter. Trek Financial LLC now owns 4,059 shares of the company's stock valued at $4,697,000 after purchasing an additional 380 shares during the period. Woodmont Investment Counsel LLC lifted its holdings in Eli Lilly and Company by 1.3% during the 3rd quarter. Woodmont Investment Counsel LLC now owns 22,467 shares of the company's stock worth $25,997,000 after purchasing an additional 284 shares in the last quarter. Finally, Traynor Capital Management Inc. lifted its holdings in Eli Lilly and Company by 1.1% during the 3rd quarter. Traynor Capital Management Inc. now owns 55,402 shares of the company's stock worth $64,104,000 after purchasing an additional 588 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,412.06 on Tuesday. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68. The business has a 50-day simple moving average of $1,200.81 and a 200 day simple moving average of $1,094.25. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.83, a PEG ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the company earned $7.02 EPS. The company's quarterly revenue was up 38.6% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's payout ratio is presently 22.46%.

Analyst Ratings Changes

A number of research firms have weighed in on LLY. Truist Financial reaffirmed a "buy" rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an "outperform" rating in a report on Friday. Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research report on Friday, September 18th. Berenberg Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price objective for the company in a research note on Tuesday, September 15th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and set a $1,450.00 price objective on shares of Eli Lilly and Company in a research note on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,404.14.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.